1. AHRO : Austin Health Research Online
  2. Austin Health research
  3. Journal articles
Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/31920
Full metadata record
DC FieldValueLanguage
dc.contributor.authorWatts, Justin M-
dc.contributor.authorBaer, Maria R-
dc.contributor.authorYang, Jay-
dc.contributor.authorPrebet, Thomas-
dc.contributor.authorLee, Sangmin-
dc.contributor.authorSchiller, Gary J-
dc.contributor.authorDinner, Shira N-
dc.contributor.authorPigneux, Arnaud-
dc.contributor.authorMontesinos, Pau-
dc.contributor.authorWang, Eunice S-
dc.contributor.authorSeiter, Karen P-
dc.contributor.authorWei, Andrew H-
dc.contributor.authorDe Botton, Stephane-
dc.contributor.authorArnan, Montserrat-
dc.contributor.authorDonnellan, Will-
dc.contributor.authorSchwarer, Anthony P-
dc.contributor.authorRécher, Christian-
dc.contributor.authorJonas, Brian A-
dc.contributor.authorFerrell, P Brent-
dc.contributor.authorMarzac, Christophe-
dc.contributor.authorKelly, Patrick-
dc.contributor.authorSweeney, Jennifer-
dc.contributor.authorForsyth, Sanjeev-
dc.contributor.authorGuichard, Sylvie M-
dc.contributor.authorBrevard, Julie-
dc.contributor.authorHenrick, Patrick-
dc.contributor.authorMohamed, Hesham-
dc.contributor.authorCortes, Jorge E-
dc.date2022-
dc.date.accessioned2023-01-12T05:14:28Z-
dc.date.available2023-01-12T05:14:28Z-
dc.date.issued2023-01-
dc.identifier.citationThe Lancet. Haematology 2023; 10(1)en_US
dc.identifier.issn2352-3026-
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/31920-
dc.description.abstractOlutasidenib (FT-2102) is a potent, selective, oral, small-molecule inhibitor of mutant isocitrate dehydrogenase 1 (IDH1). The aims for phase 1 of this phase 1/2 study were to assess the safety, pharmacokinetics, pharmacodynamics, and clinical activity of olutasidenib, as monotherapy or in combination with azacitidine, in patients with acute myeloid leukaemia or myelodysplastic syndrome, harbouring mutant IDH1.en_US
dc.language.isoeng-
dc.titleOlutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial.en_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleThe Lancet. Haematologyen_US
dc.identifier.affiliationUniversity of Miami Sylvester Comprehensive Cancer Center, Miami, FL, USA.en_US
dc.identifier.affiliationUniversity of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA.en_US
dc.identifier.affiliationKarmanos Cancer Institute, Detroit, MI, USA.en_US
dc.identifier.affiliationDepartment of Hematology, Yale University, New Haven, CT, USA.en_US
dc.identifier.affiliationDepartment of Hematology and Oncology, Weill Cornell Medicine, New York, NY, USA.en_US
dc.identifier.affiliationDavid Geffen School of Medicine at University of California, Los Angeles, CA, USA.en_US
dc.identifier.affiliationDepartment of Hematology and Oncology, Northwestern University, Chicago, IL, USA.en_US
dc.identifier.affiliationCentre Hospitalier Universitaire Bordeaux, Bordeaux, France.en_US
dc.identifier.affiliationHospital Universitari i Politècnic La Fe, Valencia, Spain.en_US
dc.identifier.affiliationRoswell Park Comprehensive Cancer Center, Buffalo, NY, USA.en_US
dc.identifier.affiliationNew York Medical College, New York, NY, USA.en_US
dc.identifier.affiliationThe Alfred Hospital and Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia.en_US
dc.identifier.affiliationInstitut Gustave-Roussy, Villejuif, France.en_US
dc.identifier.affiliationInstitut Català d'Oncologia-Hospital Duran i Reynals, IDIBELL, Hospitalet Llobregat, Barcelona, Spain.en_US
dc.identifier.affiliationSarah Cannon Research Institute at Tennessee Oncology, Nashville, TN, USA.en_US
dc.identifier.affiliationEastern Health Monash University Clinical School and Austin Hospital, Melbourne, Australia.en_US
dc.identifier.affiliationCentre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer Toulouse-Oncopole, Toulouse, France.en_US
dc.identifier.affiliationUniversity of California, Davis Comprehensive Cancer Center, Sacramento, CA, USA.en_US
dc.identifier.affiliationVanderbilt University, Nashville, TN, USA.en_US
dc.identifier.affiliationInstitut Gustave-Roussy, Villejuif, France.en_US
dc.identifier.affiliationAustin Healthen_US
dc.identifier.affiliationForma Therapeutics, Watertown, MA, USA.en_US
dc.identifier.affiliationGeorgia Cancer Center, Augusta, GA, USA.en_US
dc.identifier.doi10.1016/S2352-3026(22)00292-7en_US
dc.type.contentTexten_US
dc.identifier.pubmedid36370742-
dc.description.volume10-
dc.description.issue1-
dc.description.startpagee46-
dc.description.endpagee58-
dc.subject.meshtermssecondaryAzacitidine/adverse effects-
dc.subject.meshtermssecondaryMyelodysplastic Syndromes/drug therapy-
dc.subject.meshtermssecondaryMyelodysplastic Syndromes/genetics-
dc.subject.meshtermssecondaryLeukemia, Myeloid, Acute/drug therapy-
dc.subject.meshtermssecondaryLeukemia, Myeloid, Acute/genetics-
dc.subject.meshtermssecondaryAntineoplastic Combined Chemotherapy Protocols/adverse effects-
dc.subject.meshtermssecondaryThrombocytopenia/chemically induced-
dc.subject.meshtermssecondaryThrombocytopenia/drug therapy-
dc.subject.meshtermssecondaryFebrile Neutropenia/drug therapy-
dc.subject.meshtermssecondaryIsocitrate Dehydrogenase/genetics-
local.name.researcherSchwarer, Anthony P
item.cerifentitytypePublications-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.fulltextNo Fulltext-
item.openairetypeJournal Article-
item.grantfulltextnone-
item.languageiso639-1en-
crisitem.author.deptClinical Haematology-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

48
checked on Dec 30, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.